SCR7
Code | Size | Price |
---|
TAR-T3340-5mg | 5mg | £256.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T3340-1mL | 1 mL * 10 mM (in DMSO) | £265.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
SCR7, a specific DNA Ligase IV inhibitor, blocks nonhomologous end-joining (NHEJ).
CAS:
1533426-72-0
Formula:
C18H14N4OS
Molecular Weight:
334.4
Pathway:
Apoptosis; DNA Damage/DNA Repair; Cell Cycle/Checkpoint
Purity:
0.98
SMILES:
O=c1[nH]c(=S)[nH]c(N=Cc2ccccc2)c1N=Cc1ccccc1
Target:
Apoptosis; DNA/RNA Synthesis; CRISPR/Cas9
References
Chu VT, et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing inmammalian cells.Nat Biotechnol. 2015 May;33(5):543-8.
Srivastava M, et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell. 2012 Dec 21;151(7):1474-87.
Lin C, et al. Increasing the Efficiency of CRISPR/Cas9-mediated Precise Genome Editing of HSV-1 Virus in Human Cells. Sci Rep. 2016 Oct 7;6:34531.